Nebitrix (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebitrix, is a beta blocker presented as an oral tablet for oral use. It selectively blocks β1‑adrenergic receptors and also enhances nitric oxide release, helping to lower blood pressure and improve cardiac function in adults with hypertension or heart failure.

GNH USA supplies Nebitrix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory‑approved batches for global distribution.

Nebitrix is a selective β1‑adrenergic receptor antagonist used in the management of cardiovascular conditions. - Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. - Heart failure: improves left ventricular ejection fraction and reduces hospitalization risk in chronic heart failure. - Elderly patients with hypertension: provides effective blood pressure control with a favorable tolerability profile.

Nebitrix may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache - Dizziness - Fatigue - Nausea - Bradycardia - Peripheral edema

Serious or Rare Side Effects: - Severe bradycardia - Atrioventricular block - Bronchospasm - Allergic reactions (rash, angioedema) - Liver enzyme elevation - Worsening heart failure

When prescribing Nebitrix, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: check baseline and periodic readings. - Heart rate assessment: observe for bradycardia before and during therapy. - Asthma or COPD: use with caution due to potential bronchoconstriction. - Concomitant beta‑blockers: avoid additive effects that may cause excessive slowing. - Renal impairment: adjust dose in patients with severe renal dysfunction. - Store at room temperature: keep in the original pack, protect from moisture and heat.

Nebitrix can interact with other medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects. - Non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): increased risk of AV block. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): may raise nebivolol plasma levels. - Severe bradycardic agents (digoxin): heightened risk of bradycardia. - High‑dose ACE inhibitors combined with nebivolol: potential excessive hypotension.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure. - ACE inhibitors/ARBs: watch for additive hypotensive effect. - NSAIDs: may reduce antihypertensive efficacy. - Antidiabetic drugs: monitor glucose control as blood pressure changes can affect glycemia. - Antihistamines: observe for increased sedation or dizziness.